Abbott India Limited (ABBOTINDIA) Revenue 2023–2026

Name: Abbott India Limited (ABBOTINDIA) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Abbott India Limited annual revenue for fiscal 2026 was ₹69.3 billion, an increase of 8.1% from ₹64.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ABBOTINDIA Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹69.3B	₹64.1B	₹58.5B	₹53.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABBOTINDIA Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹18.1B	₹17.1B	₹17.2B	₹17.6B	₹17.4B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

MANKIND Revenue — Mankind Pharma Limited
4506 Revenue — Sumitomo Pharma Co., Ltd.
GLENMARK Revenue — Glenmark Pharmaceuticals Limited
ALKEM Revenue — Alkem Laboratories Limited
IPCALAB Revenue — Ipca Laboratories Limited
GLAND Revenue — Gland Pharma Limited

More ABBOTINDIA metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All ABBOTINDIA financial statements → Interactive ABBOTINDIA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.